BIODESIX INC

# Signal Note: Perceptive Initiates BDSX Position Perceptive Advisors' entry into BDSX ($739K, 108,694 shares) signals conviction in the company's diagnostic portfolio, particularly its lung cancer blood tests (Envisia Genomic Classifier, LungVesture). Edelman's track record backing clinical-stage assets suggests confidence in near-term validation data or reimbursement expansion, likely tied to upcoming Medicare coverage decisions or real-world evidence readouts that could drive adoption in oncology centers. The modest position size indicates exploratory positioning rather than core conviction, warranting monitoring of upcoming clinical/regulatory catalysts.